Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Reports Third-Quarter 2012 Results

Published: Thursday, August 16, 2012
Last Updated: Monday, August 20, 2012
Bookmark and Share
Revenues were $1.72 billion for the third fiscal quarter ended July 31, 2012, 2 percent above one year ago.

Third-quarter GAAP net income was $243 million, or $0.69 per share. Last year's third-quarter GAAP net income was $330 million, or $0.92 per share.

During the third quarter, Agilent had intangible amortization of $32 million, acquisition and integration costs of $41 million, and asset impairment and write-down charges of $15 million. The company also recognized a tax benefit of $58 million. Excluding these items and $5 million of other net charges, Agilent reported third-quarter adjusted net income of $278 million, or $0.79 per share.

Bill Sullivan, Agilent president and CEO, said, "Agilent's performance in the fiscal third quarter did not meet our revenue and EPS guidance. We have clearly entered an environment of much slower growth, resulting in deals taking longer to close and customers delaying their order deliveries.

"Despite the global environment, however, we delivered a strong operating margin performance that underscores Agilent's ability to proactively respond to rapidly changing market conditions."
Electronic Measurement third-quarter revenues were down 1 percent over the prior year. Orders declined 4 percent from the same period last year. Growth in communications was driven by wireless manufacturing and was offset by weaker aerospace and defense and industrial demand.

Chemical Analysis revenues were flat with a year ago. Orders were down 7 percent. Food and forensics markets held steady, while petrochemical and energy were impacted by the global economy.

Life Sciences revenues grew 2 percent over last year, while orders declined 2 percent year over year. Growth in the pharma market was offset by a decline in academic and government.
Diagnostics and Genomics, which includes the recent Dako acquisition, had revenues of $106 million.

Agilent generated $240 million of cash from operations in the quarter. Third-quarter ROIC was 18 percent.

Fiscal fourth-quarter 2012 revenues are expected to be in the range of $1.76 billion to $1.78 billion. Fiscal fourth-quarter non-GAAP earnings are expected to be in the range of $0.80 to $0.82 per share.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis
To assist cytogenetic labs in the clinical interpretation of microarray data.
Friday, May 30, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Agilent Appoints Senior VP and President of Life Sciences and Diagnostics Group
Fred Strohmeier, has been named senior vice president, Agilent, and president of Agilent's Life Sciences and Diagnostics Group (LDG), effective immediately.
Wednesday, December 18, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent Names Massachusetts Eye and Ear Infirmary as Certified Service Provider for NGS and aCGH Solutions
MEEI's Department of Ophthalmology Ocular Genomics Institute is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.
Thursday, October 24, 2013
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Dr. Hashim M. Al-Hashimi Receives Agilent Thought Leader Award
Agilent supports University of Michigan Professor’s work developing transformative NMR applications for structural biology.
Tuesday, April 23, 2013
Agilent and SRI International Sign Licensing Agreement
Agilents’ new pathway Architect software to include SRI International’s BioCyc Pathway database collection.
Wednesday, April 17, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!